Ariane Blog

Dr Baron from Centre Antoine Lacassagne, Nice, giving 5 year results of OPERA Trial at this year’s GEC-ESTRO event in Belgrade.

Landmark Approval: (NICE) the National Institute for Health and Care Excellence Recommends Low Energy Contact X-ray Brachytherapy (CXB) for Targeted Locally Advanced Rectal Cancer, Revolutionizing Patient Choice and Care

ALFRETON DERBYSHIRE 13TH November 2025 – Ariane Medical Systems Ltd The National Institute for Health and Care Excellence (NICE) has up dated its 2015 recommendations on the use of Low Energy X-rays in the treatment of lower rectal tumours to include operable patients who have up to a T3a-b tumour.

This positive recommendation for the use of low-energy Contact X-ray Brachytherapy (often referred to as the Papillon technique) will potentially allow thousands of patients a chance to avoid a permanent stoma usually associated with early-stage and locally advanced rectal cancer.

This pivotal decision validates the Papillon technique as a credible and highly effective healthcare process, offering a significant and transformative addition to the treatment landscape for both patients and clinicians across the UK. Prioritising Organ Preservation and Quality of Life The NICE committee thoroughly reviewed a bank of evidence, recognizing the treatment’s capacity to deliver exceptional patient outcomes. Key efficacy outcomes considered included: improved quality of life, organ preservation, avoiding a permanent stoma, clinical response, survival, and recurrence rates.

The Papillon technique allows patients to often avoid major, life-altering surgery (Total Mesorectal Excision, TME), thereby dramatically improving patient choice and overall quality of life by preserving the rectum and sphincter function. Robust Clinical Efficacy An international trial, including 4 centres in the UK (OPERA trial), has validated CXB treatment for tumours up to 3 cm in circumference and then to be combined with existing External Beam radiotherapy and chemotherapy for tumours of up to 5 cm. This combination allows larger tumours to be shrunk and the Contact X-ray Brachytherapy to be applied as a boost, dramatically increasing the likelihood of complete clinical response and organ preservation in over 80% of patients (up to 96% for those with smaller tumours who have CXB first). This approach, backed up by clinical data from the international trial called OPERA, represents a significant step forward in the non-surgical management of locally advanced rectal cancer.

Prof Arthur Sun Myint on the Papillon patient Facebook page wrote: “This guidance will be a game changer in the management of rectal cancer. As you know, surgery has always been a gold standard of care for rectal cancer. Contact X-ray Brachytherapy (CXB) is only reserved for patients not suitable for surgery (IPG532). From today CXB can be used as an option to treat all patients who are fit and suitable for surgery with operable rectal cancer not beyond cT3b cN1 (which is the majority of patients). This will change practice”.

Impact on Health Economics Beyond the clinical benefits, the recommendation is expected to have a considerable impact on health economics, by offering a highly effective, minimally invasive treatment pathway that can reduce the reliance on complex, expensive surgical interventions and long-term stoma care, Papillon CXB offers substantial savings to the NHS while enhancing patient recovery and return to normal life.

 This approval confirms the use of Contact X-ray Brachytherapy (Papillon technique) as a standard-of-care option, providing multidisciplinary teams with a validated, highly effective, non-surgical tool to manage locally advanced rectal cancer.

There are currently 4 UK locations offering this treatment with two further sites being commissioned early in the New Year.

 Papillon CXB Papillon is named after Prof Papillon who developed the treatment in Lyon in the 1960’s and was popular as a palliative treatment or an option for those unable to have major surgery. The technique all but disappeared in the 1990s when the manufacture of the old Philips RT50 stopped with just 2 doctors continuing the treatment on behalf of patients- Prof Jean-Pierre Gerard, Nice, and Prof Sun Myint, Clatterbridge cancer centre UK.

In 2005 Ariane Medical Systems was approached to make a new Low Energy system to enable this treatment to survive. Although not NICE approved, Ariane did so and the first new Contact X-ray Brachytherapy system was rolled out in 2009. Ariane now has clinicians in hospitals around Europe using their Papillon+™ Contact X-ray Brachy system to offer patients a non-surgical option in the treatment of colorectal cancer.

Media & Technical Contacts: Simon Bernard – CEO simon.bernard@arianemedicalsystems.com

Mark Davies- Cousins V.P. International Sales

mark.davies@arianemedicalsystems.com

Mobile: +44 (0) 7940359998

www.arianemedicalsystems.com

www.nice.org.uk

The final guidance for IP1724/2 – Low-energy contact X-ray brachytherapy for rectal cancer.

28 September – 1 October 2025
Moscone Centre, San Francisco

Ariane was proud to attend the American Society for Radiation Oncology (ASTRO) Annual Conference 2025, one of the world’s leading gatherings in the field of radiation oncology. Representing Ariane, Mark Davies-Cousins, VP International Sales, was on hand to connect with clinicians and partners from across the globe.

A highlight of the conference was an insightful presentation from Dr. Barbet (Macon & Villeurbanne), who shared a detailed update on the latest results from the OPERA trial, reinforcing the growing clinical evidence for Papillon CXB.

Mark also met with clinicians from New York and Hong Kong, both of whom will soon begin offering Papillon CXB as part of their planned cancer treatment programmes — a clear signal of the continued global expansion of this targeted therapy.

We are delighted to see Papillon CXB gaining momentum internationally and thank all partners and clinicians who continue to support and advocate for this innovative approach to cancer treatment.

For more information on Papillon CXB and its clinical applications, please contact:

Mark Davies-Cousins
VP International Sales
mark.davies@arianemedicalsystems.com

17–19 September 2025
Bordeaux, France

Ariane was delighted to attend this year’s SFRO Oncology Conference in Bordeaux, alongside our partners at Clerad.

The conference highlighted a major milestone for the Papillon community. With four new Papillon CXB systems now treating patients and another on the way, France has firmly reclaimed its position as one of the leading countries in the world for the use of Papillon contact brachytherapy. This innovative treatment is increasingly recognised for its impact in rectal cancer, skin cancer, and breast IORT.

Throughout the event, our team engaged with clinicians and specialists to share insights on how Papillon CXB can be integrated into cancer centres, expanding the reach of targeted treatments and improving patient outcomes.

If you would like a full briefing on how Papillon CXB could enhance your cancer treatment programme, please contact:

Mark Davies-Cousins
VP International Sales
mark.davies@arianemedicalsystems.com